Skip to main content
TipRanks
Go Ultimate75% OFF

OmniAb (OABI) Active Partners

333 Followers

Active Partners

OmniAb reported active partners of 111 in Q3 2026, up 0.9% from Q2 2026 and up 6.7% year over year. This is the highest value since 2022.

Measures how many external companies have active collaborations or licenses with OmniAb, reflecting commercial traction and demand for its antibody discovery technology. A broad, high-quality partner base reduces revenue concentration and increases potential for milestone and royalty streams, while reliance on a few large partners raises execution and revenue risk.

60.0070.0080.0090.00100.00110.00Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Active partners climbed steadily from 69 to 110, with an acceleration since 2024 that materially broadens OmniAb’s milestone and royalty runway; management’s 110 partner count and ~98% of programs with contracted economics meaningfully increases revenue visibility and supports the raised guidance. That said, the mid‑2026 flattening (107 before a small uptick) highlights variability in onboarding cadence, and milestone-driven revenue remains lumpy and tied to partner clinical timelines — partner growth lowers single-event risk but doesn’t eliminate quarter-to-quarter volatility.

OABI Active Partners

PeriodActive Partners
Q3 2026Sep 30, 2026111
Q2 2026Jun 30, 2026110
Q1 2026Mar 31, 2026107
Q4 2025Dec 31, 2025107
Q3 2025Sep 30, 2025104
Q2 2025Jun 30, 2025100
Q1 2025Mar 31, 202595
Q4 2024Dec 31, 202491
Q3 2024Sep 30, 202486
Q2 2024Jun 30, 202483
Q1 2024Mar 31, 202480
Q4 2023Dec 31, 202377
Q3 2023Sep 30, 202376
Q2 2023Jun 30, 202374
Q1 2023Mar 31, 202370
Q4 2022Dec 31, 202269

Related KPIs